Inhibition of anti-CD3 antibody-induced mouse T cell activation by pentoxifylline in combination with rapamycin or A77 1726 (leflunomide)

International Journal of Immunopharmacology

Volumn 20, Issue 4-5, 1998, Pages 241-252

  Richard, Martin ^a   Hoskin, David W ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Immunosuppression; Leflunomide; Pentoxifylline; Rapamycin; T lymphocytes

Indexed keywords

LEFLUNOMIDE; PENTOXIFYLLINE; RAPAMYCIN; TERIFLUNOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SPLEEN LYMPHOCYTE; T LYMPHOCYTE;

EID: 0031847207     PISSN: 01920561     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0192-0561(98)00029-0     Document Type: Article

References (36)

1. Bartlett, R.R., Dimitrijevic, M., Mattar, T., Zielinski, T., Germann, T., Rüde, E., Thoenes, G.H., Küchle, C.C.A., Schorlemmer, H.-U., Bremer, E., Finnegan, A., Schleyerbach, R., 1991. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions, 32, 10-21.
2. Bierer, B.E., Schreiber, S.L., Burakoff, S.J., 1991. The effect of the immunosuppressant FK506 on alternate pathways of T cell activation. Eur. J. Immunol. 21, 439-445.
3. Chen, G., Colombo, L.L., Lopez, M.C., Watson, R.R., 1996. Effect of ethanol and cocaine treatment on the immune system of v-Ha-ras-transgenic mice. Int. J. Immunopharmac. 18, 251-258.
4. Chen, H., Xu, D., Qi, S., Wu, J., Luo, H., Daloze. P., 1995. Rapamycin graft pretreatment in small bowel and kidney transplantation in the rat. Transplantation 59, 1084-1089.
5. Chong, A.S.-F., Finnegan, A., Jiang, X., Gebel, H., Sankary, H.N., Foster, P., Williams, J.W., 1993. Leflunomide, a novel immunosuppressive agent. The mechanism of inhibition of T cell proliferation. Transplantation 55, 1361-1366.
6. Depper, J.M., Leonard, W.J., Drogula, G., Kronke, M., Waldmann, T.A., Greene, W.C., 1985. Interleukin-2 augments transcription of the IL-2 receptor gene. Proc. Natl. Acad. Sci. USA 82, 4230-4234.
7. Dong, R.-P., Umezawa, Y., Ikushima, H., Munakata, Y., Shlossman, S.F., Morimoto, C., 1997. Different regulatory effects of pentoxifylline on human T cell activation pathways. J. Clin. Immunol. 17, 247-252.
8. Dumont, F.J., Staruch, M.J., Koprak, S.L., Melino, M.R., Sigal, N.H., 1990. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J. Immunol. 144, 251-258.
9. Elder, R.T., Xu, X., Williams, J.W., Gong, H., Finnegan, A., Chong, A.S.-F., 1997. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms. J. Immunol. 159, 22-27.
10. Fitzpatrick, L., Makrigiannis, A.P., Kaiser, M., Hoskin, D.W., 1996. Anti-CD3-activated killer T cells: Interferon-γ and interleukin-10 cross-regulate granzyme B expression and the induction of major histocompatibility complexunrestricted cytotoxicity. J. Interferon Cyto. Res. 16, 537-546.
11. Feuerstein, N., Huang, D., Prystowsky, M.B., 1995. Rapamycin selectively blocks interleukin-2-induced proliferating cell nuclear antigen gene expression in T lymphocyte. J. Biol. Chem. 270, 9454-9458.
12. Funk, J.O., Ernst, M., Schönharting, M.M., Zabel, P., 1995. Pentoxifylline exerts synergistic immunomodulatory effects in combination with dexamethasone or cyclosporin A. Int. J. Immunopharmac. 17, 1007-1016.
13. Ghosh, P., Tan, T.H., Rice, N.R., Sica, A., Young, H.A., 1993. The interleukin-2 CD28-responsive complex contains at least three members of the NFKB family: c-Rel, p50, and p65. Proc. Natl. Acad. Sci. USA 90, 696-700.
14. Granger, D.K., Cromwell, J.W., Chen, S.C., Goswitz, J.J., Morrow, D.T., Beierle, F.A., Sehgal, S.N., Canafax, D.M., Matas, A.J., 1995. Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy. Transplantation 59, 183-186.
15. Hecht, M., Müller, M., Lohmann-Matthes, M.-L., Emmendörffer, A., 1995. In vitro and in vivo effects of pentoxifylline on macrophages and lymphocytes derived from autoimmune MRL-lpr/lpr mice. J. Leukoc. Biol. 57, 242-249.
16. Hoskin, D.W., Phu, T., Makrigiannis, A.P., 1996. Pentoxifylline inhibits granzyme B and perforin expression following T-lymphocyte activation by anti-CD3 antibody. Int. J. Immunopharmac. 18, 623-631.
17. Kahan, B.D., Chang, J.Y., Sehgal, S.N., 1991. Preclinical evalulation of a new potent immunosuppressive agent, rapamycin. Transplantation 52, 185-191.
18. Kaiser, M., Brooks-Kaiser, J., Fitzpatrick, L., Bleackley, R.C., Hoskin, D.W., 1993. Cytotoxic cell proteinase gene expression and cytolytic activity by anti-CD3-activated cytotoxic T lymphocytes is sensitive to cyclosporin A but is not dependent on interleukin-2 synthesis. J. Leukoc. Biol. 54, 458-464.
19. Kuo, C.J., Chung, J., Fiorentino, D.F., Flanagan, W.M., Blenis, J., Crabtree, G.R., 1992. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase. Nature 358, 70-73.
20. Leo, O., Foo, M., Sachs, D.H., Samelson, L.E., Bluestone, J.A., 1987. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl. Acad. Sci. USA 84, 1374-1378.
21. Lui, C.-C., Joag, S.V., Kwon, B.S., Young, J.D.-E., 1990. Induction of perforin and serine esterases in a murine cytotoxic T lymphocyte clone. J. Immunol. 144, 1196-1201.
22. Makrigiannis, A.P., Hoskin, D.W. 1997. Inhibition of CTL induction by rapamycin: IL-2 rescues granzyme B and perforin expression but only partially restores cytotoxic activity. J. Immunol. 159, 4700-4707.
23. Maksymowych, W.P., Avina-Zubieta, A., Luong, M.H., Russel, A.S., 1995. An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J. Rheumatol. 22, 625-629.
24. Maraskovsky, E., Chen, W.-F., Shortman, K., 1989. IL-2 and IFN-γ are two necessary lymphokines in the development of cytolytic T cells. J. Immunol. 143, 1210-1214.
25. Martel, R.R., Klicius, J., Galet, S., 1977. Inhibition of the immune response by rapamycin, a new fungal antibiotic. Can. J. Physiol. Pharmacol. 55, 48-51.
26. Moller, D.R., Wysocka, M., Greenlee, B.M., Ma, X., Wahl, L., Trinchieri, G., Karp, C.L., 1997. Inhibition of human interleukin-12 production by pentoxifylline. Immunol. 91, 197-203.
27. Pimentel-Muiños, F.X., Muñoz-Fernández, M.A., Fresno, M., 1994. Control of T lymphocyte activation and IL-2 receptor expression by endogenously secreted lymphokines. J. Immunol. 152, 5714-5722.
28. Rieckmann, P., Weber, F., Gunther, A., Martin, S., Bitsch, A., Broocks, A., Kitze, B., Weber, T., Borner, T., Poser, S., 1996. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J. Neuroimmunol. 64, 193-200.
29. Rott, O., Cash, E., Fleischer, B., 1993. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur. J. Immunol. 23, 1745-1751.
30. Siemasko, K.F., Chong, A.S.-F., Williams, J.W., Bremer, E.G., Finnegan, A., 1996. Regulation of B cell function by the immunosuppressive agent leflunomide. Transplantation 61, 635-642.
31. Sykes, M., 1996. Immunobiology of transplantation. FASEB J. 10, 721-730.
32. Thanhäuser, A., Reiling, N., Böhle, A., Toellner, K.-M., Duchrow, M., Scheel, D., Schlüter, C., Ernst, M., Flad, H.-D., Ulmer, A.J., 1993. Pentoxifylline: a potent inhibitor of IL-2 and IFN-y biosynthesis and BCG-induced cytotoxicity. Immunol. 80, 151-156.
33. Tilg, H., Eibl, B., Pichl, M., Gächter, A., Herold, M., Brankova, J., Huber, C., Niederwieser, D., 1993. Immune response modulation by pentoxifylline in vitro. Transplantation 56, 196-201.
34. Vidic-Dankovic, B., Kosec, D., Damjanovic, M., Apostolski, S., Isakovic, K., Bartlett, R.R., 1995. Leflunomide prevents the development of experimentally induced myasthenia gravis. Int. J. Immunopharmac. 17, 273-281.
35. Woerly, G., Brooks, N., Ryffel, B., 1996. Effect of rapamycin on the expression of the IL-2 receptor (CD25). Clin. Exp. Immunol. 103, 322-327.
36. Xu, X., Blinder, L., Shen, J., Gong, H., Finnegan, A., Williams, J.W., Chong, A.S.-F., 1997. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. J. Immunol. 159, 167-174.